OTLK · OUTLOOK THERAPEUTICS INC

-

Please sign in to comment on OTLK

1 Comment

Admin

4 years ago

Outlook Therapeutics, Inc is currently in a long term uptrend where the price is trading 40.2% above its 200 day moving average.

From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.3.

Outlook Therapeutics, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.

Its net income has increased by 12.9% to $-14M since the same quarter in the previous year.

Finally, its free cash flow fell by 99.7% to $-13M since the same quarter in the previous year.

Based on the above factors, Outlook Therapeutics, Inc gets an overall score of 3/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	NASDAQ
CurrencyCode	USD
ISIN	US69012T2069

PE Ratio	None
Target Price	10
Beta	0.47
Market Cap	49M
Dividend Yield	None

ABOUT

OUTLOOK THERAPEUTICS INC

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.

OTLK · OUTLOOK THERAPEUTICS INC

-

OUTLOOK THERAPEUTICS INC

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest OUTLOOK THERAPEUTICS INC using a moving average strategy